Alfonso Iorio is Professor and Chair, Department of Health Research Methods, Evidence, and Impact at McMaster University Canada. He is Director of the Health Information Research Unit (HiRU, http://hiru.mcmaster.ca/hiru) and of the Hamilton-Niagara Hemophilia Program. He received his medical and PhD degrees from the University of Perugia, Italy.

He is the Principal Investigator of the Web Application for Population Pharmacokinetic in Hemophilia (WAPPS) project (www.wapps-hemo.org), co-investigator of the Patient Reported Outcomes, Burden, and Experiences (PROBE), and Chair of the Canadian Bleeding Disorders Registry (CBDR). He is past-chair of the WFH Data and Demographics committee, and co-chair of the World Bleeding Disorders Registry (WBDR).

He is Associate Editor for bleeding disorders of the Cochrane Collaboration, Thrombosis Research, and serves on the Editorial Boards of numerous journals including the Journal of Thrombosis and Haemostasis, and Haemophilia.

Outside Hemophilia, his current research interests include internet-based knowledge dissemination, systematic review and meta-analysis methodology, risk prediction and stratification, and artificial intelligence application to all of them.

He has authored over 300 peer reviewed papers totaling over 20,000 citations and a H-index of 59 (details available on his personal page Google Scholar). He has given many lectures, including educational lectures at many international conferences.

Alisa S. Wolberg is a Professor and Vice-Chair of Basic Science Research in the Department of Pathology and Laboratory Medicine at UNC. Dr. Wolberg previously served as a Councilor of the International Society on Thrombosis and Haemostasis (ISTH, 2016-2022), Chair of the 2018 Hemostasis Gordon Research Conference, Scientific Co-Chair of the 2020 American Society of Hematology (ASH) Annual Meeting, Chair of the 2025 Hemostasis Thrombosis Research Society (HTRS) meeting, Chair of Basic Science of the 2025 ISTH meeting. She is currently Chair of the ASH Committee on Scientific Affairs and serves as an Associate Editor of Blood Advances. Dr. Wolberg directs a basic and translational research lab focused on contributions of abnormal blood coagulation and fibrinolytic proteins to health and disease. Current projects focus on fibrin(ogen), factor XIII, and red blood cells in thrombosis; mechanisms in cancer-associated thrombosis and hormone-associated thrombosis; and mechanisms that mediate clot formation, structure, and stability in hemophilia and factor XI deficiency. She has a deep commitment to mentoring and supporting the next generation of blood scientists. s

Dr. Davide Matino is an Associate Professor of Medicine (Division of Hematology and Thromboembolism) at McMaster University, Hamilton, ON, Canada. Dr. Matino’s main research interests include hemophilia A and B, novel therapies for bleeding disorders, and the pharmacokinetic of clotting factor concentrates in hemophilia A and B. He is an active clinical trial investigator involved in numerous trials in the field of thrombosis and haemostasis with a specific focus on novel therapies for hemophilia, such as gene therapy, gene editing, FVIII-mimetic molecules, and coagulation rebalancing agents. Dr. Matino also directs a basic research lab investigating roles and functions of coagulation factor VIII and factor IX, funded by the Canadian Institutes of Health Research program and several industry-funded research grants. Dr. Matino is a member of the Novel Therapies Committee of the Association of Hemophilia Clinic Directors of Canada (AHCDC) and a member of the International Society on Thrombosis and Haemostasis (ISTH) 2025 Inherited Bleeding Disorders Theme Committee.

As the Chief Science Officer (CSO) for ATHN, Dr. Tami Chrisentery-Singleton, works at the strategic and policy level to inform the scientific direction of ATHN. She works across the organization to define, develop, and implement ATHN’s science and research capabilities as well as to ensure ATHN’s commitment to public health. Additionally, she cares for adult and pediatric hematology patients at the Ochsner Center for Hemostasis and Thrombosis.

Dr. Singleton's areas of special interest include sickle cell disease, rare blood disorders, gene therapy, and musculoskeletal ultrasound in hemophilia patients. She has authored numerous publications and led more than 60 clinical trials and research studies—including serving as the principal investigator for ATHN 16: Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients with Hemophilia A or B with Inhibitors and ATHNTranscends: A Natural History Cohort Study.

Before joining ATHN, Dr. Singleton was the Chief of Pediatric Hematology and Director of the Hemophilia Treatment Center for the Louisiana Center for Advanced Medicine. She also previously served as the Chief of Pediatric Hematology and Oncology, the Director of the Sickle Cell Center of South Louisiana, and the Associate Director of the Louisiana Center for Bleeding and Clotting Disorders at the Tulane University School of Medicine/Tulane Hospital for Children.